Chinese RNA Therapy Developers Extend Fundraising Streak Into December

 
• By Dexter Jie Yan

In the latest venture capital and private equity funding deals in China, SanegeneBio, Argo Biopharma and Ausper Biopharma raised a combined $136m on the back of their early-stage small interfering RNA and antisense oligonucleotide assets.

FUNDING word written on wood block
SanegeneBio financing one of biggest in RNA to date in 2023 • Source: Shutterstock

More from China

More from Focus On Asia